Could a 3-Day antibiotic course beat the standard 7 days for chlamydia?
NCT ID NCT05840159
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed phase 4 trial tested whether taking doxycycline for 3 days works as well as the usual 7-day course for treating chlamydia. About 526 men and women with confirmed chlamydia took either a 3-day or 7-day regimen, with placebo pills used to keep the study blinded. Participants were tested again 28 days later to see if the infection was cleared.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- doxycycline
- What this could lead to
- If successful, this could show that a shorter 3-day course of doxycycline is just as effective as the standard 7-day course for treating chlamydia, potentially simplifying treatment.
- What could go wrong
- This is a completed phase 4 trial, so results are available. However, the shorter regimen may not be as effective in all patients, and the study only looked at specific groups (women with urogenital infection and men with rectal infection).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHLAMYDIAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital Midtown - Emory Clinic Infectious Diseases
Atlanta, Georgia, 30308, United States
-
Grady Memorial Hospital
Atlanta, Georgia, 30303, United States
-
KEMRI-CCR PHRD Project
Thika, Kenya
-
Pwani Research Centre
Mombasa, Kenya
-
University of Alabama at Birmingham School of Medicine - Infectious Disease
Birmingham, Alabama, 35222, United States
-
University of Rochester Medical Center - Vaccine Research Unit
Rochester, New York, 14642-0001, United States
-
University of Washington - Harborview Medical Center - Center for AIDS and STD
Seattle, Washington, 98104-2433, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.